Art. -Nr.: HY-N0568

Madecassoside

(Synonyms: Asiaticoside A)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB, exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.58%
CAS. Nr.: 34540-22-2
Formel: C₄₈H₇₈O₂₀
Molecular Weight:975.12

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Madecassoside Chemical Structure

CAS. Nr.: 34540-22-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB^[5]^[6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity^[10]. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

In Vitro

Madecassosid (30, 100 μmol/L, 12 h) increases cell viability of oxidative injuried human umbilical vein endothelial cells (HUVECs)^[5].
Madecassosid (10-100 μmol/L, 12 h) inhibits phosphorylation of p38 MAPK and activaty of Caspase-3, and therefore exhibits an antiapoptotic activity^[5].
Madecassosid (10-100 μg/L) exhibits anxioxidative activity against melanocyte dendtrites retraction, maintaining mitochondrial membrane potential and Ca²⁺ homeostasis^[7].
Madecassosid (30 μM) improves Insulin secretion by increasing expressions of p-IRS1, Akt and p-Akt under glucotoxic conditions^[8].
Madecassosid (10 μM, 24 h) prevents inflammation and autophagy of neuronal cells induced by Aβ_25–35 through the class III PI3K/Beclin-1/Bcl-2 pathway^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[5]

Cell Line:

HUVECs
Concentration:

10, 30, 100 μmol/L
Incubation Time:

12 h
Result:

Increased cell viability to 68.9% and 78.3%, with concentration of 30 and 100 μmol/L, respectively.

Western Blot Analysis^[5]

Cell Line:

HUVECs
Concentration:

10, 30, 100 μmol/L
Incubation Time:

12 h
Result:

Inhibited phosphorylation in p38 MAPK.

In Vivo

Madecassosid (6, 12, 24 mg/kg, i.v.) resolves neurological deficit and ameliorates neuronal apoptosis after focal cerebral ischemia reperfusion^[6].
Madecassosid (6, 12, 24 mg/kg, i.v) inhibits activity of NF-kB and so prevents the brain injury^[6].
Madecassosid (120 mg/kg, i.g.) reduces LPS-induced neurotoxicity and enhances heme oxygenase proteins via upregulation of Nrf2 in LPS-stimulated neurotoxicity^[10].
Madecassosid (10-40 mg/kg,p.o.) ameliorates oxidative damage and imflammation after bleomycin (BLM) instillation, inhibits TGF-β1 overexpression and collagen synthesis, improves collagen degradation^[11].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Focal cerebral ischemia reperfusion injury in Sprague Dawley rats^[6]
Dosage:

6, 12, 24 mg/kg
Administration:

Intravenous injection
Result:

Reduced neurological deficit, infarct area, brain damage and neuronal apoptosis.

Animal Model:

Lipopolysaccharide-induced neurotoxicity in Sprague-Dawley rats^[10]
Dosage:

30-120 mg/kg for 14 days
Administration:

Intraperitoneal injection
Result:

Reduced LPS-induced cognitive impairment and imflammatory cytokine, promoted Nrf2 pathway at concentration of 120 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 34540-22-2
Appearance Solid
Molecular Weight 975.12
Formel C₄₈H₇₈O₂₀
Color White to off-white
SMILES

O=C(C1(CCC(C)C2C)C2C3=CCC4C(C)(CC(O)C5C4(CC(O)C(O)C5(C)CO)C)C3(C)CC1)OC(C(C(O)C6O)O)OC6COC(C(C(O)C7OC(OC(C)C(O)C8O)C8O)O)OC7CO
Synonyms

Asiaticoside A
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayWBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Int J Pharm

3D-printed microneedles loaded with madecassoside for periodontal soft tissue regeneration. [Abstract]

2025 Apr 12:125569. PMID: 40228613

Madecassoside purchased from MedChemExpress. Usage Cited in: Int J Pharm. 2025 Apr 12:125569. [Abstract]

Madecassoside at 10 μM and 15 μM promoted cell proliferation (P < 0.05), and the difference between 10 μM and 15 μM was statistically significant at 3 and 5 d (P < 0.05). On day 5, the promotion effect on the cells was the most obvious (P < 0.001).

Madecassoside purchased from MedChemExpress. Usage Cited in: Int J Pharm. 2025 Apr 12:125569. [Abstract]

Relative protein expression of COL-I in HGFs after 1, 3, and 5 d of Madecassoside application at 5, 10, and 15 μM. The results showed that Madecassoside at 5 μM significantly increased the level of type I collagen in HGFs.
J Biochem Mol Toxicol

Madecassoside Improves Renal Injury via Activation of AMPK/Autophagy in Experimental Membranous Nephropathy. [Abstract]

2025 Sep;39(9):e70509. PMID: 40952770

Madecassoside purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2025 Sep;39(9):e70509. [Abstract]

Effects of Madecassoside (MA, 30 mg/kg; i.p.; once daily for 4 weeks) on biochemical parameters of rats (after drug administration). These results indicate that MA relieves MN-induced renal dysfunctions in rats.

Madecassoside purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2025 Sep;39(9):e70509. [Abstract]

Renal tissues in sham, sham + Madecassoside (MA), model, and model + MA groups were investigated by staining with hematoxylin-eosin, PAS, and Masson and photographed by a light microscope. The results showed that Madecassoside (MA, 30 mg/kg; i.p.; once daily for 4 weeks) significantly improved the pathological condition of the mesangium and interstitium in rats with membranous nephropathy (MN), significantly reduced ECM deposition, and partially alleviated glomerular fibrosis lesions and interstitial dilation in rats.

Madecassoside purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2025 Sep;39(9):e70509. [Abstract]

Madecassoside (MA, 30 mg/kg; i.p.; once daily for 4 weeks) obviously restored these protein levels in membranous nephropathy (MN) rats.
Narra J

Thymoquinone and madecassoside improve motor function in a rotenone-induced mouse model of early Parkinson's disease: Role of dopamine, alpha-synuclein and mBDNF. [Abstract]

2025 Aug;5(2):e2439. PMID: 40951472

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (102.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 33.33 mg/mL (34.18 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0255 mL

5.1276 mL

10.2551 mL

5 mM

0.2051 mL

1.0255 mL

2.0510 mL

10 mM

0.1026 mL

0.5128 mL

1.0255 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zexin Li et al. Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway. Int Immunopharmacol. 2016 Apr;33:24-32. [Content Brief]

[2]. Xia Y et al. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-γ in colon. Br J Pharmacol. 2016 Apr;173(7):1219-35 [Content Brief]

[3]. Su Z et al. Protective effects of madecassoside against Doxorubicin induced nephrotoxicity in vivo and in vitro. Sci Rep. 2015 Dec 14 [Content Brief]

[4]. Anukunwithaya, et al., Pharmacokinetics of a Standardized Extract of Centella asiatica ECa 233 in Rats. Planta Med. 2017 May;83(8):710-717. [Content Brief]

[5]. Bian D, et al., Madecassoside, a triterpenoid saponin isolated from Centella asiatica herbs, protects endothelial cells against oxidative stress. J Biochem Mol Toxicol. 2012 Oct;26(10):399-406. [Content Brief]

[6]. Luo Y, et al., Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res. 2014 May 27;1565:37-47. [Content Brief]

[7]. Ling Y, et al., Protective effect of madecassoside on H2O2-induced oxidative stress and autophagy activation in human melanocytes. Oncotarget. 2017 May 7;8(31):51066-51075. [Content Brief]

[8]. Elhassen SAM, et al., Effect of madecassoside and catalpol in amelioration of insulin sensitivity in pancreatic (INS-1E) β-cell line. Nat Prod Res. 2021 Nov;35(22):4627-4631. [Content Brief]

[9]. Du B, et a;., Madecassoside prevents Aβ(25-35)-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway. Int Immunopharmacol. 2014 May;20(1):221-8. [Content Brief]

[10]. Liu S, et al., Madecassoside ameliorates lipopolysaccharide-induced neurotoxicity in rats by activating the Nrf2-HO-1 pathway. Neurosci Lett. 2019 Sep 14;709:134386. [Content Brief]

[11]. Lu GX, et al., Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen deposition. Phytother Res. 2014 Aug;28(8):1224-31. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.0255 mL	5.1276 mL	10.2551 mL	25.6379 mL
	5 mM	0.2051 mL	1.0255 mL	2.0510 mL	5.1276 mL
	10 mM	0.1026 mL	0.5128 mL	1.0255 mL	2.5638 mL
	15 mM	0.0684 mL	0.3418 mL	0.6837 mL	1.7092 mL
	20 mM	0.0513 mL	0.2564 mL	0.5128 mL	1.2819 mL
	25 mM	0.0410 mL	0.2051 mL	0.4102 mL	1.0255 mL
	30 mM	0.0342 mL	0.1709 mL	0.3418 mL	0.8546 mL
DMSO	40 mM	0.0256 mL	0.1282 mL	0.2564 mL	0.6409 mL
	50 mM	0.0205 mL	0.1026 mL	0.2051 mL	0.5128 mL
	60 mM	0.0171 mL	0.0855 mL	0.1709 mL	0.4273 mL
	80 mM	0.0128 mL	0.0641 mL	0.1282 mL	0.3205 mL
	100 mM	0.0103 mL	0.0513 mL	0.1026 mL	0.2564 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Madecassoside

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Madecassoside

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Anti-Aging Natural Product Library

Pain-Related Compound Library

Protease Inhibitor Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Madecassoside

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Madecassoside Related Classifications

HY-N0568 Related Classifications